Discontinue Escitalopram and Increase Bupropion for SSRI-Induced Bruxism
Taper escitalopram 10 mg to 5 mg daily for 1-2 weeks, then discontinue; simultaneously increase bupropion XL from 150 mg to 300 mg daily after 4-7 days of the escitalopram taper.
Rationale for Medication Changes
SSRI-associated bruxism is a well-documented phenomenon that occurs in both pediatric and adult patients, most commonly in females. Fluoxetine, sertraline, and escitalopram are frequently reported offending agents. Symptoms typically begin within 3-4 weeks of medication initiation and resolve within 3-4 weeks of drug discontinuation 1. Given this patient's bruxism is clearly attributable to escitalopram, discontinuation is appropriate.
Bupropion is an effective alternative for MDD and GAD, with approximately 60% of patients resistant to SSRIs experiencing full or partial response when switched to bupropion 2. The FDA label supports bupropion as first-line treatment for MDD 3.
Escitalopram Taper Protocol
Reduce escitalopram from 10 mg to 5 mg daily for 1-2 weeks, then discontinue completely.
Escitalopram/citalopram are shorter-acting SSRIs that require gradual tapering to minimize discontinuation syndrome 4. The discontinuation syndrome includes dizziness, fatigue, myalgias, headaches, nausea, insomnia, paresthesias, anxiety, and irritability 4.
While some evidence suggests hyperbolic tapering over months may further reduce withdrawal symptoms 5, a conservative 1-2 week taper from 10 mg to 5 mg before complete cessation is clinically practical for this dose level and balances withdrawal risk against prolonged exposure to the causative agent 6, 7.
Critical caveat: Monitor closely during the taper for withdrawal symptoms versus depression relapse. Withdrawal symptoms typically emerge within days of dose reduction and improve over 1-2 weeks, while relapse develops more gradually 8, 7.
Bupropion Dose Escalation
Increase bupropion XL from 150 mg to 300 mg daily after 4-7 days of starting the escitalopram taper.
The FDA-approved dosing for bupropion XL in MDD is 150 mg daily for 4 days, then increase to target dose of 300 mg daily 3. The maximum dose is 300 mg daily for bupropion XL formulation 3.
Timing strategy: Begin the bupropion increase early in the escitalopram taper (after 4-7 days at 5 mg escitalopram) rather than waiting for complete SSRI discontinuation. This provides antidepressant coverage during the transition and addresses the anxiety component, as bupropion has demonstrated efficacy in patients with MDD and co-occurring anxiety symptoms 9, 10.
Safety Considerations
Monitor for these specific risks:
Seizure risk: Bupropion lowers seizure threshold. The gradual dose escalation minimizes this risk. Contraindicated if history of seizures, eating disorders, or abrupt benzodiazepine/alcohol discontinuation 11, 6, 3.
Activation/anxiety: Bupropion can initially increase anxiety or agitation 6, 12. However, this typically resolves within 1-2 weeks and should not preclude use in GAD patients 9, 10.
Neuropsychiatric effects: Monitor for worsening depression, suicidal ideation, agitation, or behavioral changes, particularly in the first 4-8 weeks 11, 12, 3. Discontinue immediately if these emerge.
Drug interactions: No significant interaction between escitalopram and bupropion. Escitalopram has minimal CYP450 effects 4. However, avoid MAOIs—allow 14 days between MAOI discontinuation and bupropion initiation 3.
Hydroxyzine continuation: Continue hydroxyzine 50 mg PRN for anxiety management during the transition period, as it provides additional anxiolytic coverage without seizure risk or serotonergic interactions.
Follow-Up Schedule
- Week 1-2: Assess withdrawal symptoms, anxiety levels, and depression severity
- Week 2-4: Confirm escitalopram discontinuation tolerance and bupropion response
- Week 4-8: Evaluate full therapeutic response to bupropion 300 mg daily
- Monitor bruxism resolution: Should improve within 3-4 weeks of escitalopram discontinuation 1
If bruxism persists after escitalopram discontinuation, consider dental evaluation for primary bruxism or other contributing factors.